Squamous carcinoma model of humoral hypercalcemia of malignancy.

Squamous carcinomas are the most common cause of humoral hypercalcemia of malignancy (HHM) in humans. To develop an animal model of this syndrome, CD-1 female mice were painted with dimethylbenzanthracene, which produced cutaneous squamous carcinomas in the majority of those painted. Greater than 90% of tumor-bearing mice developed a syndrome of hypercalcemia, hypophosphatemia, hypercalciuria, elevated plasma 1,25-dihydroxyvitamin D, normal immunoreactive PTH, elevated urinary cAMP, and accelerated bone resorption compared to control mice. Tumor excision reversed the hypercalcemia and hypophosphatemia, and autopsies revealed no evidence of skeletal or other metastases. Dietary calcium restriction did not affect the hypercalcemia in tumor-bearing mice. Extracts of tumor tissue contained potent bioactivity paralleling that of bovine (b) PTH in a PTH-sensitive canine renal cortical adenylate cyclase assay. The activity was trypsin sensitive and partially inhibitable by Nle, Tyr bPTH amide. The activity coeluted with chymotrypsinogen (mol wt, 25,700) on Sephacryl S-200 chromatography, well ahead of bPTH. This is the first description of an animal squamous carcinoma that produces HHM. With the exception of elevated plasma 1,25-dihydroxyvitamin D levels, the syndrome precisely mimics that seen in human HHM. The presence of a biologically active protein larger than PTH in tumor extracts, similar to that extracted from human tumors, suggests a common mode of pathogenesis. This model should be useful in further studying the pathophysiology of HHM.

[1]  R. Baron,et al.  Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. , 1984, Endocrinology.

[2]  S. Ralston,et al.  Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. , 1984, Clinical science.

[3]  A. Vignery,et al.  Evidence of sequential remodeling in rat trabecular bone: Morphology, dynamic histomorphometry, and changes during skeletal maturation , 1984, The Anatomical record.

[4]  G. Mundy,et al.  Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. , 1983, The New England journal of medicine.

[5]  J. Hayslett,et al.  Evidence for bidirectional net movement of creatinine in the rat kidney. , 1983, The American journal of physiology.

[6]  K. Kosaka,et al.  Association of hypercalcemia with tumors producing colony-stimulating factor(s). , 1983, Cancer research.

[7]  A. F. Stewart,et al.  Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Strewler,et al.  Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors. , 1983, The Journal of clinical investigation.

[9]  T. Martin,et al.  The hypercalcemia of malignancy: pathogenesis and management. , 1982, Metabolism: clinical and experimental.

[10]  A. Verma,et al.  Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen. , 1982, Cancer research.

[11]  R. Baron,et al.  Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. , 1982, The Journal of clinical endocrinology and metabolism.

[12]  B. Roos,et al.  Secondary hyperparathyroidism in X-linked hypophosphatemic mice. , 1982, Endocrinology.

[13]  R. Gray,et al.  Abnormal vitamin D metabolism in the X-linked hypophosphatemic mouse. , 1980, Endocrinology.

[14]  Patricia A. Johnson,et al.  Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. , 1980, The Journal of clinical endocrinology and metabolism.

[15]  R. Lynch,et al.  Plasmacytoma spleen colonization: a sensitive, quantitative in vivo assay for idiotype-specific immune suppression of MOPC-315. , 1978, Journal of immunological methods.

[16]  B. Riggs,et al.  Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. , 1974, The American journal of medicine.

[17]  J. Potts,et al.  Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. , 1973, The New England journal of medicine.

[18]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[19]  C. H. Fiske,et al.  THE COLORIMETRIC DETERMINATION OF PHOSPHORUS , 1925 .

[20]  J. Potts,et al.  Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Broadus Nephrogenous cyclic AMP. , 1981, Recent progress in hormone research.

[22]  L. Sherwood,et al.  6 – Disorders of Mineral Metabolism in Malignancy , 1978 .